With Medicare prescription-drug benefits on the brink of a shake-up, enrollees who hope to minimize their costs at the pharmacy counter next year need to stay vigilant in the coming months.
More Stories
Why Constellation Energy and Vistra shares are building on massive gains
Constellation has a new nuclear-power deal with Microsoft. Both Constellation and Vistra shares have more than doubled this year on...
Why Fed bets were so out of whack: Waller explains what put him ‘over the edge’ for a jumbo rate cut
Inflation might actually fall too far, Fed governor says.
FTC sues prescription-drug middlemen over insulin prices, says drugmakers are also ‘on notice’
Pharmacy-benefit managers owned by CVS, Cigna and UnitedHealth “artificially inflated” prices for lifesaving medications, regulator alleges.
‘Powell delivered the stock market to the Promised Land.’ Why the S&P 500 could soar past 6,000 by year-end.
Yardeni: Odds of a 1990s-like market boom have increased after Fed rate-cut.
Small-cap stocks post longest rally since 2021 after Fed rate cut. What’s next?
Small-cap stocks just saw their longest winning streak in three and a half years, after the Federal Reserve recalibrated its...
Traders face biggest index rebalancing in four years on Friday: Here’s what to watch for
Investors are facing the busiest quarterly rebalancing in about four years on Friday in a shakeup that could impact roughly...